Breaking AI & Tech News Analyzed

In the heart of Buxton lies a remarkable wood, a self-willed and entangled haven of willows and birch, teeming with life. This site, boasting a species list of 870, primarily composed of insects, has become a beacon of biodiversity. The wood's diversity is largely attributed to the presence of willows and birch, two pioneer trees known for their invertebrate-friendly nature.The connection between insect abundance and birdsong is well-established, as the music of birds is fueled largely by invertebrate protein. A recent dawn-chorus walk in the area revealed 20 early spring vocalists, including song and mistle thrushes, dunnocks, wrens, bullfinches, and greenfinches, many of which are red- or amber-listed by the British Trust for Ornithology.However, the term 'dawn chorus' can be misleading, as the songs begin as early as 3:40 am and reach their peak around 4:30 am, long before the first light of dawn. The birds sing to proclaim territories and entice partners, leading to a complex harmony of competing voices. This phenomenon is beautifully described by Bernie Krause in his book The Great Animal Orchestra, which explores how the soundscape of any place reflects a kind of collective harmonizing among its inhabitants.It is disheartening, therefore, that High Peak borough council's plans threaten to disrupt this harmony. Despite declaring a nature emergency, the council appears unwilling to protect Hogshaw wood, instead considering it for a 'land bank' for development. This decision is particularly concerning given that the site is largely owned by the council and is one of the richest in nature in the area. The question remains: what is the meaning of declaring a nature emergency if it is not backed by concrete actions to protect and preserve our natural treasures?

Tens of thousands of people have been hired by Scale AI – a firm 49% owned by Meta – to train artificial‑intelligence models by scraping Instagram accounts, harvesting copyrighted artwork and transcribing pornographic soundtracks, according to the Guardian.Scale AI promotes its Outlier platform as a flexible, expert‑driven marketplace, recruiting professionals from medicine, physics and economics to "become the expert that AI learns from."Workers, however, say the reality diverges sharply from high‑level model refinement. They describe tasks that involve massive personal‑data scraping and content that many find morally uncomfortable.Outlier is managed by Scale AI, which holds contracts with the U.S. Pentagon and other defense companies. Its chief executive, Alexandr Wang, is hailed by Forbes as the world’s youngest self‑made billionaire, while former managing director Michael Kratsios served as science adviser to former President Donald Trump.One contractor noted that users of Meta platforms would be shocked to learn their photos and friends’ images are being harvested for AI training, with workers manually reviewing profiles to extract data.The Guardian interviewed ten Outlier contributors – many also journalists, graduate students, teachers or librarians – who took the gig work out of economic desperation. One said, "A lot of us were really desperate" and felt compelled to accept the unstable, low‑pay assignments.These gig workers, dubbed “taskers,” often feel they are training their own replacements, expressing “internalised shame and guilt” over contributing to the automation of creative professions.Law firm Clarkson, representing AI gig workers, estimates that hundreds of thousands of people worldwide now labor on platforms like Outlier. Taskers report bait‑and‑switch recruitment tactics, where advertised high salaries are replaced by lower‑paid projects after onboarding.All contributors are monitored through a tool called Hubstaff, which can screenshot browsers to verify work. While Scale AI claims the software is only for accurate payment, workers describe it as constant surveillance.Assignments have ranged from transcribing pornographic audio and labeling photos of dead animals or dog faeces, to annotating diagrams of infant genitalia and violent police scenarios. One doctoral student recounted being promised “no nudity” only to receive explicit porn clips.Scale AI says it shuts down any task flagged as inappropriate and does not accept projects involving child sexual‑abuse material or pornography, though workers note that publicly available images of minors have been used for training.Social‑media scraping tasks required workers to tag individuals by name, location and age, sometimes pulling data from accounts of users under 18. One task asked contributors to order Facebook photos by the subject’s age, prompting ethical unease.In addition to personal data, taskers were asked to harvest copyrighted artwork, with strict instructions to avoid AI‑generated images and select only hand‑drawn pieces. Scale AI maintains it does not ask workers to violate copyright standards.Scale AI’s client list includes major tech firms such as Google, Meta and OpenAI, as well as the U.S. Department of Defense and the government of Qatar, highlighting the growing demand for labelled data as AI models scale.Some workers reported interacting with ChatGPT and Claude, and speculated they might be training Meta’s upcoming model, code‑named “Avocado.”OpenAI announced it ended its partnership with Scale AI in June 2025, citing its supplier code of conduct that mandates ethical treatment of all workers.Despite irregular pay, occasional mass layoffs and the unsettling nature of many tasks, many taskers remain on the Outlier platform, hoping the AI future will eventually improve conditions. One said, "I have to be positive about AI because the alternative is not great."In response, a Scale AI spokesperson stated, "Outlier provides flexible, project‑based work with transparent pay. Contributors choose when and how they participate, and we regularly hear from highly skilled contributors who value the flexibility and opportunity to apply their expertise on the platform."

US President Donald Trump has issued a stern warning to Iran, stating that the Tuesday deadline for Tehran to agree to free passage through the Strait of Hormuz is final. Failure to comply will result in US strikes on Iranian infrastructure, he emphasized.On Monday, Trump described an Iranian proposal aimed at ending the conflict as 'a significant step' but insufficient to avert US action. The proposal, which includes 10 clauses such as an end to conflicts in the region, a protocol for safe passage through the Strait of Hormuz, the lifting of sanctions, and reconstruction, was conveyed to the US via intermediaries.The Iranian proposal was put forward after Pakistan suggested a 45-day ceasefire, which Iran reportedly rejected, seeking a permanent end to hostilities instead. Iran's diplomatic mission head in Cairo, Mojtaba Ferdousi Pour, stressed that Tehran would only accept an end to the war with guarantees that it wouldn't be attacked again.The Strait of Hormuz, a critical waterway through which about 20% of the world's oil supplies pass, has been a focal point of the conflict. Trump's threat to destroy Iranian infrastructure unless the strait is reopened has caused oil prices to surge and shaken the global economy.Earlier on Monday, Israel struck a key petrochemical plant in Iran's South Pars gas field, killing two commanders of the Islamic Revolutionary Guard Corps. Israel claimed responsibility for the strike, which appeared separate from Trump's threats.The White House confirmed that a ceasefire proposal was under consideration but stated that Trump had 'not signed off' on it. The conflict, sparked by Israeli and US attacks on Iran on February 28, has seen Iran fire missiles at targets across the Middle East.Trump has been vocal about his stance, suggesting that Iran's leaders are 'animals' who have killed tens of thousands of protesters and expressing that he is 'highly unlikely' to postpone the deadline. When asked about concerns that attacks on infrastructure could be classified as war crimes, Trump responded that he is 'not worried about it,' emphasizing that allowing Iran to have a nuclear weapon would be a greater war crime.

The Grand National continues to be a major highlight in the horse racing calendar, with its enduring popularity and cultural significance in the UK. Despite ongoing concerns about horse welfare, the event has seen a decrease in serious injuries and fatalities in recent years, thanks in part to modifications made to the course.The Grand National has a long history dating back to 1839 and remains one of the most-watched and highly bet-on events in the sport. While animal rights groups continue to criticize the race, citing concerns over horse safety, the sport's governing bodies have implemented various measures to minimize risks.In recent years, there has been a steady reduction in the number of fallers in the National, with data showing a decline from 8-8-4-4-6-4-5-4-4-0-3 fallers between 2014 and 2025. The 2024 and 2025 runs, with easier fences and a maximum field of 34, recorded the lowest and third-lowest numbers of fallers this century.Despite these improvements, fatalities still occur, and the RSPCA has called for lessons to be learned from recent incidents, emphasizing that 'one death is too many.' The organization has highlighted the need for continued vigilance and improvement in horse welfare and safety protocols.The racing community continues to evolve, with jockeys and trainers working to balance the thrill of competition with the imperative of protecting the animals involved. As the sport prepares for upcoming events, including the Grand National, there is a renewed focus on safety, welfare, and the integrity of the sport.

Mayor Claudia Kalisch, vice‑president of the German Federation of Cities and leader of the Green‑party city of Lüneburg, announced a push for a nationwide ban on night‑time use of robotic lawnmowers. The proposal aims to curb injuries and deaths among hedgehogs and other small nocturnal animals that frequent residential gardens after dark.Recent research has highlighted that the fast‑moving blades of autonomous mowers pose a hidden danger to wildlife active between dusk and dawn. Hedgehogs, which often curl into a ball when threatened, are especially difficult for mower sensors to detect.Kalisch told the Funke newspaper group that urban green spaces have become critical refuges as development and intensive agriculture shrink natural habitats. She noted that petitions urging the ban have amassed tens of thousands of signatures earlier this year, reflecting broad public concern.In addition to legislative pressure, the mayor called on manufacturers to develop hedgehog‑friendly technology. She emphasized that industry responsibility is essential for protecting biodiversity and improving city life quality.The European red‑list classifies hedgehogs as "near threatened" since 2024, after a documented 30% population decline over the past decade. Beyond mower hazards, motorised leaf blowers, vacuums, and vehicle collisions—responsible for up to one in three fatalities—exacerbate the species’ decline across Europe.Scientists at the University of Oxford, in collaboration with Danish colleagues, recently demonstrated that hedgehogs can hear high‑frequency ultrasound, opening the possibility of sonic road repellers to deter them from dangerous areas. The same team has produced 3D‑printed, crash‑test dummy hedgehogs to work with manufacturers on a future certification scheme for "hedgehog‑safe" mowers.Study co‑author Anne Berger of Germany’s Leibniz Institute for Zoo and Wildlife Research warned that injuries from robotic mowers place an "enormous burden" on animal‑care centres, with many victims discovered days or weeks after the incident, enduring prolonged suffering.German law already protects hedgehogs, imposing fines of up to €65,000 for illegal trapping, injury, or killing. Several cities—including Cologne, Leipzig and Munich—have already outlawed night‑time mower operation. However, a recent attempt by the Greens to enact a statewide ban in Bavaria was rejected.

The deployment of reflective mirrors on satellites and the launch of thousands more satellites into low Earth orbit could have significant consequences for human health and ecosystems. Leading sleep and circadian rhythm researchers have raised concerns about the potential disruption to natural night-time light environments.The US Federal Communications Commission (FCC) is considering plans by Reflect Orbital to illuminate parts of the Earth at night using reflective satellites, as well as applications from SpaceX that could dramatically expand satellite numbers in low Earth orbit.2,500 researchers from over 30 countries have expressed concerns that altering the light-dark cycle could disrupt biological clocks that regulate sleep and hormone secretion in humans and animals, migration in nocturnal species, seasonal cycles in plants, and the rhythms of marine phytoplankton.Prof Charalambos Kyriacou, president of the European Biological Rhythms Society (EBRS), emphasized that "plants need the night" and that eliminating it could have global implications for food security.Reflect Orbital aims to use satellites equipped with large reflective mirrors to redirect sunlight onto areas roughly 5km to 6km wide "on demand", with brightness adjustable "from full moon to full noon".Meanwhile, SpaceX has proposed launching up to 1m satellites to create a giant solar-powered computing network in orbit designed to run artificial-intelligence workloads.Ruskin Hartley, chief executive of DarkSky International, noted that scientific studies have already shown that the existing number of satellites in orbit has increased diffuse night sky brightness by roughly 10%.Experts warn that if current trends in satellite launches and debris generation continue, night sky brightness could increase substantially over the coming decade, approaching the threshold astronomers have set for preserving naturally dark skies.

The UK government has announced that it will not pursue a ban on foie gras imports and will not restrict fur imports, citing the need to prioritize trade agreements with the EU. This decision reverses a previous commitment to restrict the import of these products, which are often associated with animal cruelty.The move has been criticized by animal welfare charities, who argue that the UK's high animal welfare standards should not be compromised for the sake of trade agreements. The RSPCA and other organizations have expressed disappointment and concern about the impact on animal welfare.The UK had previously banned fur farming in 2000 and the production of foie gras in 2006, but imports of these products have continued. The EU has made it clear that it will not allow member states to ban each other's products on animal welfare grounds, which has limited the UK's ability to restrict imports.The decision is seen as a significant concession to the EU as the UK seeks to secure a trade deal. The government has stated that it is prioritizing economic growth and has set up a working group to examine the fur industry.Animal welfare charities and some businesses are urging the government to reconsider its decision and maintain its commitment to banning these products. Some restaurants and shops have already removed foie gras from their menus and shelves, citing concerns about animal welfare.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.